Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA®▼(Dengue ...

Despite the muted success of Sanofi's Dengvaxia in the global market, Globaldata analysts forecast a rosy outlook for Qdenga.

Germany's defence minister is confident its fractious ruling coalition can agree on a new model of military service in time ...

The U.S. Supreme Court holds oral arguments on Wednesday over the legality of President Donald Trump's tariffs imposed under ...

The 2026 NFL Draft is still six months away, but the upcoming class is already starting to take shape. Take a look at our ...

Findings from a phase 3 trial show Qdenga, Takeda's live-attenuated dengue vaccine, provided 61.2% vaccine efficacy against ...

The proportion of participants achieving HbA1c < 7.0% and a =10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide ...

Following the Federal Reserve's 25-basis-point reduction yesterday, markets are awash with liquidity, encouraging a risk-on ...

With the crypto market regaining its bull phase, savvy investors are zeroing in on the best crypto to invest in before the next significant leg up. Cardano (ADA ...

Markets have entered a curious phase. Equities continue to push new highs, liquidity is abundant, and global rate cuts are underpinning optimism across ...

CME sees record XRP futures trading as institutional demand rises amid Ripple’s legal win, ETF speculation, and growing ...